Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

TH-9507 proceeds to toxicological studies

Dec. 10, 1997

BioTime reports preliminary phase III data from Hextend trial

Dec. 9, 1997

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Dec. 9, 1997

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Dec. 9, 1997

HMR begins phase II trial with GA-EPO

Dec. 8, 1997

Sanofi in-licenses antidiabetic drug from Bayer

Dec. 4, 1997

New inhibitor of inflammatory bone resorption presented at Tokyo congress

Dec. 4, 1997

Vitronectin receptor antagonists described by Hoechst

Dec. 4, 1997

Bayer develops CETP inhibitors

Dec. 4, 1997

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Dec. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...